# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Reshape Lifesciences (NASDAQ:RSLS) reported quarterly losses of $(0.06) per share. This is a 94.44 percent increase over losses...
Maxim Group analyst Anthony Vendetti downgrades Reshape Lifesciences (NASDAQ:RSLS) from Buy to Hold.
Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global ma...
https://patentcenter.uspto.gov/applications/16865242/ifw/docs
-SEC